AC-699 is under clinical development by Accutar Biotechnology and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AC-699’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AC-699 is under development for the treatment of estrogen receptor positive or human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. The drug candidate is an orally bioavailable estrogen receptor degrader.
Accutar Biotechnology overview
Accutar Biotechnology (Accutar Biotech) is a biotechnology company that employs artificial intelligence to revolutionize drug discovery. It is headquartered in Brooklyn, New York, the US.
For a complete picture of AC-699’s drug-specific PTSR and LoA scores, buy the report here.